Danielle Brill Analyst PerformanceManaging Director at Truist FinancialDanielle Brill is a stock analyst at Truist Financial focused in the medical sector, covering 26 publicly traded companies. Over the past year, Danielle Brill has issued 55 stock ratings, including strong buy, buy, and hold recommendations. While full access to Danielle Brill's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Danielle Brill's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings73 Last 8 YearsBuy Recommendations88.57% 62 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution70RatingsDistribution of strong buy, buy, hold, and sell ratings by Danielle Brill.RatingPercentageCount Strong Buy4.3%3 ratings Buy84.3%59 ratings Hold11.4%8 ratings Sell0.0%0 ratingsOut of 70 total stock ratings issued by Danielle Brill at Truist Financial, the majority (84.3%) have been Buy recommendations, followed by 11.4% Hold and 4.3% Strong Buy.Best & Worst CallsBest Call0000.0%SAGEAug 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%SAGEDec 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ26 companiesDanielle Brill, an analyst at Truist Financial, currently covers 26 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies96.2%Finance1 company3.8%Danielle Brill of Truist Financial specializes in stock coverage within the Medical sector, with additional focus on Finance companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE21 companies80.8%MED - DRUGS2 companies7.7%MED - GENERIC DRG1 company3.8%REAL ESTATE INVESTMENT TRUSTS1 company3.8%PHARMACEUTICAL PREPARATIONS1 company3.8% Danielle Brill's Ratings History at Truist Financial Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIMVTImmunovant5/22/2026Boost Price Target$34.71$30.00Hold$0.0000.00% ROIRAPPRapport Therapeutics5/18/2026Initiated Coverage$35.18$56.00Buy$0.0000.00% ROIINSMInsmed5/13/2026Lower Price Target$118.12$185.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines5/13/2026Boost Price Target$336.61$715.00Buy$0.0000.00% ROIHRMYHarmony Biosciences5/8/2026Boost Price Target$31.50$29.00Hold$0.0000.00% ROINBIXNeurocrine Biosciences5/7/2026Boost Price Target$148.38$155.00Buy$0.0000.00% ROIWVEWAVE Life Sciences4/29/2026Initiated Coverage$7.52$15.00Buy$0.0000.00% ROIBBIOBridgeBio Pharma4/29/2026Boost Price Target$69.75$102.00Buy$0.0000.00% ROIMAZEMaze Therapeutics4/14/2026Lower Price Target$27.42$64.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals4/13/2026Lower Price Target$326.98$505.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CLYMClimb Bio3/17/2026Initiated Coverage$7.12$17.00Buy$0.0000.00% ROIMAZEMaze Therapeutics3/17/2026Initiated Coverage$50.39$68.00Buy$0.0000.00% ROIAPGEApogee Therapeutics3/17/2026Initiated Coverage$69.85$83.00Hold$0.0000.00% ROICLYMClimb Bio3/17/2026Upgrade$7.12Strong-Buy$0.0000.00% ROIMAZEMaze Therapeutics3/17/2026Upgrade$48.47Strong-Buy$0.0000.00% ROIDNTHDianthus Therapeutics3/9/2026Boost Price Target$65.20$110.00Buy$0.0000.00% ROIIRONDisc Medicine2/27/2026Lower Price Target$66.23$83.00Buy$0.0000.00% ROIBBIOBridgeBio Pharma2/25/2026Boost Price Target$65.76$95.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics2/24/2026Set Price Target$120.41$210.00$0.0000.00% ROIHRMYHarmony Biosciences2/23/2026Downgrade$29.16Hold$0.0000.00% ROINBIXNeurocrine Biosciences2/17/2026Lower Price Target$129.47$140.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals1/29/2026Boost Price Target$24.89$38.00Buy$0.0000.00% ROIINSMInsmed1/12/2026Set Price Target$166.83$205.00$0.0000.00% ROITECXTectonic Therapeutic1/8/2026Lower Price Target$21.27$60.00Buy$0.0000.00% ROIHRMYHarmony Biosciences1/8/2026Lower Price Target$37.49$45.00Buy$0.0000.00% ROIIMVTImmunovant1/8/2026Boost Price Target$26.31$22.00Hold$0.0000.00% ROIDNTHDianthus Therapeutics1/8/2026Boost Price Target$38.55$63.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals1/8/2026Boost Price Target$22.40$33.00Buy$0.0000.00% ROIBBIOBridgeBio Pharma1/8/2026Boost Price Target$74.42$86.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals1/8/2026Lower Price Target$413.44$530.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences1/8/2026Lower Price Target$137.11$169.00Buy$0.0000.00% ROIINSMInsmed12/19/2025Initiated Coverage$166.55$202.00Buy$0.0000.00% ROIINSMInsmed12/18/2025Upgrade$174.84Strong-Buy$0.0000.00% ROIPVLAPalvella Therapeutics12/15/2025Boost Price Target$87.67$190.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics11/10/2025Boost Price Target$80.00$105.00Buy$0.0000.00% ROIIRONDisc Medicine11/10/2025Boost Price Target$82.86$114.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals11/5/2025Set Price Target$20.89$30.00$0.0000.00% ROIBBIOBridgeBio Pharma10/30/2025Reiterated Rating$66.62$80.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences10/30/2025Reiterated Rating$138.02$172.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals10/17/2025Boost Price Target$487.26$535.00Buy$0.0000.00% ROIBefore you buy SpaceX shares, consider this alternative approach (Ad)SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.Discover the overlooked SpaceX IPO strategy before the June listingIMVTImmunovant10/14/2025Initiated Coverage$17.35$16.00Hold$0.0000.00% ROIUPBUpstream Bio10/14/2025Initiated Coverage$20.08$47.00Buy$0.0000.00% ROIDNTHDianthus Therapeutics10/14/2025Initiated Coverage$34.42$56.00Buy$0.0000.00% ROIUPBUpstream Bio10/14/2025Initiated Coverage$21.69$47.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics10/2/2025Boost Price Target$61.75$80.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals9/2/2025Initiated Coverage$401.00Market Perform$0.0000.00% ROIHRMYHarmony Biosciences7/21/2025Initiated Coverage$35.20$48.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics7/21/2025Initiated Coverage$29.51$56.00Buy$0.0000.00% ROITECXTectonic Therapeutic7/21/2025Initiated Coverage$21.91$64.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences7/21/2025Initiated Coverage$132.02$163.00Buy$0.0000.00% ROIBBIOBridgeBio Pharma7/21/2025Initiated Coverage$46.51$66.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals7/21/2025Initiated Coverage$15.69$30.00Buy$0.0000.00% ROIJCAPJernigan Capital7/21/2025Initiated Coverage$16.70$24.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/21/2025Initiated Coverage$320.53$385.00Buy$0.0000.00% ROIIRONDisc Medicine7/21/2025Initiated Coverage$57.77$86.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
